期刊
IUBMB LIFE
卷 63, 期 9, 页码 764-771出版社
WILEY-BLACKWELL
DOI: 10.1002/iub.502
关键词
four and a half LIM domain protein 3; breast cancer; cell growth; cell cycle
资金
- Major State Basic Research Development Program [2011CB504202, 2007CB914603]
- National Natural Science Foundation [81072173, 81071954, 30872939, 30625035]
- National Key Technologies R&D Program for New Drugs [2009ZX09301-002]
Four and a half LAM domain (FHL) protein 3 is a member of the FHL protein family that plays roles in the regulation of signal transduction, cell adhesion, survival, and mobility. FHL3 has been implicated in the development and progression of liver cancer. However, the biological function of FHL3 in other cancers remains unclear. Here, we show that FHL3 is downregulated in breast cancer patients. Using small interfering RNA (siRNA) knockdown and/or overexpression experiments, we demonstrated that FHL3 suppressed anchorage-dependent and -independent growth of human breast cancer cells. The antiproliferative effects of 1411,3 on breast cancer cell growth were associated with both the G1 and the G2/M cell cycle arrest, which was accompanied by a marked inhibition of the G1-phase marker cyclin D1 and the G2/M-phase marker cyclin HI as well as the induction of the cyclin dependent kinase inhibitor 1)21 (WAF1/CIP1), a negative regulator of cell cycle progression at G1 and G2. These results suggest that FHL3 may play a role in the development and progression of breast cancer, and thereby may be a potential target for human breast cancer gene therapy. (C) 2011 IUBMB IUBMB Life, 63(9): 764-771, 2011
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据